Focused on immunology-based therapies for infectious diseases, this biotech company reported a notable insider sale in recent ...

Vir Biotechnology (NASDAQ:VIR) reported first-quarter 2026 financial results and provided pipeline updates, highlighting ...

Q1 2026 Management View "Since our last earnings call in February, we have remained highly focused on execution as we advance both our oncology and hepatitis delta programs with speed and focus." ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Vir Biotechnology's recent share price rally is driven by their promising cancer program, despite their primary focus on hepatitis management. The company's market cap has surged past $1 billion, ...

・Vir secured $335 million in upfront and near-term payments from its global collaboration with Astellas to advance VIR-5500. ・The company’s Phase 1 data for VIR-5500 showed promising safety and ...

VIR's is expected to report data in January from two phase 1 trials of VIR-5500 and VIR-5818, two T-cell engagers, in various cancer types. JANX recently produced promising data with JANX007, which is ...

Vir Biotechnology, Inc. (NASDAQ:VIR) is one of the best low priced biotech stocks to invest in. On April 13, Vir Biotechnology, Inc. (NASDAQ:VIR) announced that the first patient had been dosed in one ...

– Compelling early clinical response signals for VIR-5818 and VIR-5500 in heavily pretreated patients with various solid tumors VIR-5818: In patients receiving doses ≥400 µg/kg, tumor shrinkage ...

Vir Biotechnology Reports Positive Updated Phase 1 Results for PSMA-targeting, PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer – Updated Phase 1 ...

The US Government’s Biomedical Advanced Research and Development Authority (BARDA) has made an initial investment of approximately $55 million for rapid development of VIR-2482, the Vir ...